1.29  -0.06 (-4.44%)		10-28 16:00
Open: 1.34 High: 1.35 Volume: 164,708		Pre. Close: 1.35 Low: 1.255 Market Cap: 35(M)

Short term
Mid term
Targets	6-month :	1.61	1-year :	1.88
Resists	First :	1.37	Second :	1.61
Pivot price	1.23
Supports	First :	1.22	Second :	1.12
MAs	MA(5) :	1.22	MA(20) :	1.24
	MA(100) :	1.15	MA(250) :	1.21
MACD	MACD :	0	Signal :	-0.1
%K %D	K(14,3) :	61.1	D(3) :	40.1
RSI	RSI(14): 55.6
52-week	High :	1.67	Low :	0.97

Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.
[ ANTX ] has closed below upper band by 21.4%. Bollinger Bands are 48.1% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 1 days. This is a sign that the current trend might continue.

If tomorrow:	Open lower	Open higher
High:	1.35 - 1.36	1.36 - 1.37
Low:	1.24 - 1.25	1.25 - 1.25
Close:	1.28 - 1.29	1.29 - 1.3

AN2 Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing treatments for rare, chronic, and serious infectious diseases. It is developing epetraborole, a once-daily oral treatment for patients with chronic non-tuberculous mycobacterial lung disease. The company was incorporated in 2017 and is headquartered in Menlo Park, California.

Tue, 28 Oct 2025
AN2 Therapeutics Gains 11%, Insider Trades Reap Benefit - simplywall.st

Thu, 04 Sep 2025
Here's Why We're Watching AN2 Therapeutics' (NASDAQ:ANTX) Cash Burn Situation - simplywall.st

Tue, 12 Aug 2025
AN2 Therapeutics Commences First-in-Human Clinical Trial of Oral AN2-502998 for Chagas Disease - Yahoo Finance

Tue, 12 Aug 2025
AN2 Therapeutics Reports Second Quarter 2025 Financial Results and Recent Business and Scientific Highlights - Business Wire

Wed, 23 Jul 2025
AN2 Therapeutics and DNDi Collaborate on Clinical Development of Promising New Oral Compound to Treat Chronic Chagas Disease - Yahoo Finance

Thu, 01 May 2025
AN2 Therapeutics Reports Data from the Phase 3 Portion of Previously Terminated EBO-301 Study and Outlines Future Milestones from Boron Chemistry Pipeline - Business Wire

Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.	Outperform
Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).	Underperform
Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.	Neutral
Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.	Underperform
Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.	Underperform
Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.	Underperform

Exchange: NASDAQ
Sector: Healthcare
Industry: Biotechnology
Shares Out	27 (M)
Shares Float	18 (M)
Held by Insiders	25.4 (%)
Held by Institutions	39.5 (%)
Shares Short	41 (K)
Shares Short P.Month	59 (K)

EPS	-1.25
EPS Est Next Qtrly	0
EPS Est This Year	0
EPS Est Next Year	0
Book Value (p.s.)	2.51
Profit Margin	0 %
Operating Margin	0 %
Return on Assets (ttm)	-26.6 %
Return on Equity (ttm)	-44.8 %
Qtrly Rev. Growth	0 %
Gross Profit (p.s.)	0
Sales Per Share	0
EBITDA (p.s.)	0
Qtrly Earnings Growth	0 %
Operating Cash Flow	-36 (M)
Levered Free Cash Flow	-22 (M)

PE Ratio	-1.04
PEG Ratio	0
Price to Book value	0.51
Price to Sales	0
Price to Cash Flow	-1

Dividend	0
Forward Dividend	0
Dividend Yield	0%
Dividend Pay Date	Invalid DateTime.
Ex-Dividend Date	Invalid DateTime.